Intensity Therapeutics shares more than double on promising cancer trial data

** Intensity Therapeutics’s shares INTS rocket 128.6% to $0.62 premarket

** Co’s experimental cancer drug, INT230-6, showed encouraging results in patients with advanced cancers, according to a study published in Lancet’s eBioMedicine

** INTS says INT230-6 showed 75% disease control rate in advanced cancers – eBioMedicine

** Drug injected directly into tumors; shrank untreated tumors in 20% of patients, co says

** Co Median survival was 11.9 months; rose to 21.3 months in sarcoma patients

** Up to last close, stock was down ~85% YTD